热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　高盛发布研报称，维持金斯瑞生物科技（01548）“买入”评级，目标价从29.13港元降至27.34港元。该行预计随着2025年许可收入的能见度提高，ProBio毛利率将继续复苏，管理层表明预计2025年起集团整体可持续录得盈利，相应地高盛将金斯瑞今明两年每股盈测调整为亏损7美仙及转赚5美仙。

　　高盛指出，金斯瑞生物科技撇除附属公司传奇生物以外业务于2024年下半年表现大致符合预期，令全年销售额达到早前指引的下限，生命科学业务（LSG）保持稳定增长，ProBio在低基数上呈现复苏态势，订单数量增加主要来自欧美客户的驱动，而工业合成产品平台百斯杰（Bestzyme）则增长强劲。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.